Trial Profile

A Phase 2 Open-label, Long-term Extension Safety Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis (EXPEDITION OLE)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 01 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Brazikumab (Primary) ; Brazikumab (Primary)
Indications Ulcerative colitis
Focus Adverse reactions
Acronyms Expedition; EXPEDITION OLE
Sponsors AbbVie; Allergan; AstraZeneca

Most Recent Events

08 Mar 2024 This trial has been Discontinued in Italy (End date : 2023-06-01) according to European Clinical Trials Database record.
08 Nov 2023 Status changed from active, no longer recruiting to discontinued due to strategic decision to discontinue the development of brazikumab in inflammatory bowel disease.
31 Oct 2023 This trial has been discontinued in Poland, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com